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Central neuropathic pain (CNP) is a significant problem after spinal cord injury (SCI).
Pharmacological and non-pharmacological approaches may reduce the severity, but
relief is rarely substantial. While deep brain stimulation (DBS) has been used to treat
various chronic pain types, the technique has rarely been used to attenuate CNP after
SCI. Here we present the case of a 54-year-old female with incomplete paraplegia who
had severe CNP in the lower limbs and buttock areas since her injury 30 years prior. She
was treated with bilateral DBS of the midbrain periaqueductal gray (PAG). The effects of
this stimulation on CNP characteristics, severity and pain-related sensory function were
evaluated using the International SCI Pain Basic Data Set (ISCIPBDS), Neuropathic Pain
Symptom Inventory (NPSI), Multidimensional Pain Inventory and Quantitative Sensory
Testing before and periodically after initiation of DBS. After starting DBS treatment,
weekly CNP severity ratings rapidly decreased from severe to minimal, paralleled by
a substantial reduction in size of the painful area, reduced pain impact and reversal
of pain-related neurological abnormalities, i.e., dynamic-mechanical and cold allodynia.
She discontinued pain medication on study week 24. The improvement has been
consistent. The present study expands on previous findings by providing in-depth
assessments of symptoms and signs associated with CNP. The results of this study
suggest that activation of endogenous pain inhibitory systems linked to the PAG can
eliminate CNP in some people with SCI. More research is needed to better-select
appropriate candidates for this type of therapy. We discuss the implications of these
findings for understanding the brainstem’s control of chronic pain and for future progress
in using analgesic DBS in the central gray.
Keywords: neuromodulation, low-frequency stimulation, periaqueductal gray, pain severity, evoked pain,
chronic pain
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INTRODUCTION
Persistent neuropathic pain is a common and serious
consequence of spinal cord injury (SCI) that is especially
refractory to both pharmacological and non-pharmacological
treatments (Siddall et al., 2003; Vranken, 2009; Finnerup et al.,
2014). Electrical stimulation of specific brain structures with the
purpose of relieving chronic pain has been used for a long time
but the reported efficacy for central neuropathic pain (CNP)
is relatively low and difficult to predict. For certain patients,
effects of stimulation on CNP may be tremendous (Boccard
et al., 2013; Pereira and Aziz, 2014). Nevertheless, because deep
brain stimulation (DBS) is an invasive procedure, its use for SCI
pain is rare and currently restricted to severe cases refractory to
non-invasive therapies. In order to be accepted as a therapy for
chronic pain, success rates need to improve. This will require,
inter alia, a better understanding of CNP mechanisms along
with improved patient selection.
The present article describes an almost complete reversal
of CNP (which had been present since injury 30 years ago)
and associated sensory dysfunction paralleled by a reduction in
psychosocial impact in a 54-year-old female with SCI-related
CNP who underwent DBS of the periaqueductal gray (PAG). The
optimization of stimulation parameters and the time-course of
daily changes in general pain intensity over a 42-week period
were previously reported for this subject and one other with
SCI-related chronic pain (Hentall et al., 2016). Here we provide
a more detailed analysis specifically focusing on the CNP below
the level of injury evaluating a broader set of pain characteristics,
somatosensory function and psychosocial impact conducted at
intervals over a 52-week period. We also conducted an exit
interview to obtain her personal perspectives on her pain and
treatments. The ‘‘Discussion’’ Section contains a brief review of
possible mechanisms underlying successful amelioration of CNP
by DBS and the prospects for improving treatment efficacy.
BACKGROUND
Clinical History
The subject was a 54-year-old female veteran with an incomplete
SCI (T11 level) due to electrocution 30 years ago. Examination
according to the International Standards for Neurological
Classification of SCI classified her injury as AIS-B (sensory but
no motor function preserved).
The patient’s worst pain problem was chronic below-level
CNP in both lower extremities, with onset shortly after her
initial injury. The average weekly pain level for this specific pain
preceding the baseline measurement was 8 of 10 on a numerical
rating scale (NRS). CNPwas daily and constant, andmost intense
during the night and therefore significantly interfering with
sleep. She reported severe ‘‘electric’’ and moderate ‘‘stabbing’’
pain, moderate to severe evoked pain in response to brushing,
severe evoked pain to cold stimuli and moderate tingling and
pins and needles in the painful area. She was taking a daily
dose of 75 mg pregabalin for the pain but had previously tried
a wide range of pharmacological options (including opiates and
higher doses of pregabalin) and she said: ‘‘Medication? I don’t
like medication. I don’t like the way it makes me feel. I don’t like
the side effects. It . . . They all leave me feeling stupid and foggy
and disoriented and . . . So, that’s why I wouldn’t take them until
I absolutely just couldn’t . . .’’
Pain and Sensory Assessments
Pain was evaluated with respect to location, classification,
intensity, temporal pattern and pain interference using the
International SCI Pain Basic Dataset (ISCIPBDS; Widerström-
Noga et al., 2014). Neuropathic pain symptom severity was
evaluated with the Neuropathic Pain Symptom Inventory (NPSI;
Bouhassira et al., 2004), and psychosocial impact with the
Multidimensional Pain Inventory-SCI version (Widerström-
Noga et al., 2006). Sensory function was assessed below the
level of injury in the neuropathic pain area with the TSA-II
Neurosensory Analyzer (Medoc Ltd., Ramat Yishai, Israel),
either via a thermode or a vibratory pin applied to the
painful area below the level of injury. Thresholds for cool
detection, warm detection, cold pain, hot pain and vibration
detection were determined using the method of limits (reaction-
time inclusive). We also evaluated thermal allodynia using
thermorollers (Somedic, Sweden), and mechanical allodynia
using a soft brush and Semmes-Weinstein monofilaments (10 g,
#5.07). Further details regarding all QST procedures can be
found in a previous publication (Widerström-Noga et al., 2016).
Baseline pain testing was performed twice in the subject (1 and 5
weeks before the first surgery) and baseline results were averaged.
For a study timeline see Figure 1.
DBS Surgery
The work was performed under an Investigative Device
Exemption of the U.S. Food and Drug Administration
(IDE G120202), and Clinical Trials.gov (NCT02006433).
FIGURE 1 | (A) Timeline of study. The subject underwent a comprehensive
pain assessment (entire battery of pain tests) on week 2, prior to the two
surgical procedures performed on weeks 6 and 7. This was followed by
biweekly brief pain assessments (average pain intensity ratings past 7 days by
patient in clinic) and periodic repeat comprehensive assessments
postoperatively (weeks 20, 32 and 52). (B) Average pain intensity ratings past
7 days through duration of the study. Immediately following activation of the
device the subject noticed a profound reduction of her central neuropathic
pain (CNP).
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All study procedures were approved by the University of Miami
Institutional Review Board (IRB) with written consent from the
subject in accordance with the Declaration of Helsinki.
Two surgeries were performed 1 week apart: (1) bilateral
implantation of electrode leads (Medtronic3387S-40) in the
anterolateral PAG with the subject awake; and (2) connection
of both leads to extension cables under general anesthesia and
tunneling to a generator (Activa PC Neurostimulator 37601,
Medtronic). Stimulation was briefly tested during the first
surgery, eliciting an emotional response in the subject due to
near-complete relief of her long-standing symptoms. For more
details see Hentall et al. (2016).
RESULTS
The subject reported a rapid and profound improvement in
her CNP, from severe to minimal intensity, when the DBS
device was activated on the day after the second surgery. Her
DBS stimulation settings were adjusted in periodic office visits
(monthly, later every 2 months). In addition, the stimulator
was programmed with several blinded choices of parameters
(frequency or voltage) for selection at home (Hentall et al., 2016).
Among salient findings reported previously, she preferred a very
lowmean pulse rate (0.67 Hz) and the pain level took several days
to shift to a new steady state when the blinded stimulation setting
was changed. The blinded choice of settings (ineffective 0.1 V
vs. effective 4.5 V) also allowed exclusion of potentially powerful
placebo effects.
Figure 1B shows a time-line of the subject’s average weekly
CNP intensity following her DBS procedure. Whereas she
typically reported a pain intensity of 7–8 at baseline, following
the procedure her median reported CNP intensity was 2 and
remained so the length of the study. The subject also noted a
significant decrease in the size of the painful area (Figure 2). Pain
medication was discontinued by the 17th postoperative week.
The rapid reduction in overall neuropathic pain symptom
severity after initiation of DBS was maintained over the course
of the study (Figure 3A). Evoked pain was reduced to a minimal
level. Paresthesia/dysesthesia (pins and needles and tingling) in
the painful area also decreased to a significantly lower level.
Before surgery, the subject exhibited both dynamic
mechanical allodynia evoked by very weak vibratory stimuli and
static mechanical allodynia in the painful area in response to
punctuate stimuli applied with the von Frey filament (100 g).
Cold allodynia was evoked within a normally non-noxious
range, between 22.9◦C and 25.2◦C. After onset of DBS treatment,
however, there were no signs of allodynia in the painful area,
consistent with the reduction in pain symptoms. Vibratory
stimuli at the threshold level for perception and the punctuate
stimulus applied with the large von Frey filament (300 g; 6.65) did
not evoke pain after DBS was initiated. Cool and warm detection
thresholds were in the normal range (Figure 3B). Although she
initially perceived pain at the maximal temperature (50◦C), both
cold and hot stimuli within the default minimum/maximum
temperatures of 0◦C and 50◦C did not evoke a pain sensation at
follow-up.
FIGURE 2 | The area of neuropathic pain was greatly reduced in the
subject with activation of the device. Whereas before surgery (A) her pain
was located at the anterior and posterior aspects of both legs and the
superior buttocks, by the 20th week after surgery (B) pain was only perceived
below the ankles. By the 32nd postoperative week (C) the pain extended
back up to her mid-calf region of both legs and remained unchanged the
remainder of the study (D).
Though formal neurocognitive evaluation was not performed,
the Beck depression inventory (BDI), MPI-SCI subscales,
perceived life control and affective distress did not indicate any
negative effects of the DBS (Supplementary Figure S1). The BDI
scores are not shown because the subject never scored above ‘‘1’’
(including the baseline assessments). Indeed, placement of the
PAGDBS device had a tremendous positive impact on the quality
of life of the subject. During a qualitative interview after the
surgery she stated ‘‘It’s a whole new world. I’m learning my body
all over again. It’s life-changing. It still brings tears to my eyes’’.
The DBS device has remained activated with consistent efficacy
reported by the patient since implantation over 2 years ago.
DISCUSSION
Electrical stimulation of the PAG significantly reduced the
intensity and distribution of CNP-related symptoms and
associated abnormal sensory signs (i.e., mechanical and thermal
allodynia) in our subject and, consequently, had a profound
effect on her quality of life. The consistent beneficial effects
on multiple aspects of CNP over the entire study period and
the blinded choice of settings controlling for potential placebo
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FIGURE 3 | Reduction of Neuropathic Pain Symptom Inventory (NPSI)
and QST test scores with device activation. (A) The top graph shows
paroxysmal, evoked and paresthesia/dysesthesia scores, all of which were
reduced to minimal levels with stimulation. The bottom graph shows the
reduction in the NPSI sum score. (B) Effects on QST measures. Whereas the
subject had significant allodynia before surgery in response to cold and warm,
these stimuli within the default minimum/maximum temperatures (0◦C and
50◦C, respectively) did not evoke pain sensations in follow-up.
effects (Hentall et al., 2016) supports the validity of this case
report. Despite 30 years of limited pain relief with various
pharmacological treatments she had near-complete relief of her
CNP with activation of the DBS device. Such profound and
long-lasting improvements in people with CNP pain are rarely
reported with conservative measures or other surgical options
(Vranken, 2009; Cardenas et al., 2013; Gao et al., 2016).
DBS for Neuropathic Pain
DBS has been used for the treatment of various types of pain since
the 1970s, following advances in implantable stimulation devices
and the influence of Melzack and Wall’s (1965) gate theory.
Most evidence available supports the PAG as a useful stimulation
target (Pereira and Aziz, 2014). In addition to ascending
somatosensory projections, the PAG receives significant inputs
from the prefrontal cortex (PFC) and amygdala and then projects
to nucleus raphe magnus (NRM) and locus coeruleus (LC) in
the midbrain and dorsal horn neurons in the spinal cord (Van
Bockstaele et al., 1991; Li et al., 2016). Recent case series on
DBS for chronic neuropathic pain, which have utilized superior
FIGURE 4 | Illustration showing the central role of the periaqueductal
gray (PAG) in the modulation of various descending pain systems.
Various neurotransmitter systems have been implicated in the treatment of
central pain. The PAG has strong ascending and descending connections with
each of these systems and is thus in a strong position to modulate CNP.
Conventions for the arrows are shown at the bottom left of the figure. ACC,
anterior cingulate cortex; Amyg, amygdala; PFC, prefrontal cortex; LC, locus
coeruleus; NRM, nucleus raphe magnus; NTS, nucleus tractus solitarius.
targeting methods compared to earlier studies and multi-day
trials with an externalized electrode prior to final implantation,
suggest clinically-relevant improvements of pain symptoms in
67%–83% of patients with heterogeneous types of pain (Boccard
et al., 2013). Gray et al. (2014) showed that beyond improving
pain symptoms, DBS may also improve mood, anxiety and
quality of life. However, very few studies have examined the pain
reducing ability of DBS in people with CNP. The acceptance
of this therapy in the U.S. has been hindered by the variability
of outcomes. Even in cases where patients respond favorably
to a several day trial with an externalized stimulator prior to
permanent implantation, roughly a quarter of those patients
do not experience benefit 1 year after surgery (Boccard et al.,
2013).
The recent renewal of interest in DBS for chronic pain has
arisen from various factors: (1) improved safety of DBS in
general; (2) success with other indications for DBS; (3) advances
in imaging and targeting methods; and (4) renewed recognition
by the public and health administrators of the detrimental
effects of prolonged opioidmedication (Schofferman et al., 2014).
For patients with CNP of whose etiological or pathological
classification is known to make it particularly refractory to
typical treatment interventions, particularly if they have failed
to respond to conservative measures over many years, DBS
may offer benefits. The challenge is to determine which pain
phenotypes and patients are most likely to respond. This is an
especially hard problem in populations with CNP stemming
from CNS injuries, in which multiple pain mechanisms are likely
to operate simultaneously (Carlton et al., 2009; Hari et al., 2009;
Zeilig et al., 2012; Finnerup et al., 2014).
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Possible Mechanisms of DBS for CNP
Spontaneous and evoked excitability within the somatosensory
system is normally well-controlled by ascending and descending
pain pathways (Basbaum and Fields, 1984; Vranken, 2009).
CNP after spinal injury may arise as a consequence of the
amplification of signals in residual sensory neurons by spinal
and supraspinal processes, such as astrocytic and microglial
activation, ultimately influencing various neurotransmitter
systems, local connectivity and cytokines (Scholz and Woolf,
2007; Zeilig et al., 2012; Finnerup et al., 2014; Robinson et al.,
2016).
The raphe nuclei and their associated modulatory
neurotransmitter, serotonin, have long been implicated as
important factors influencing pain. However, although selective
serotonin reuptake inhibitors are among the most prescribed
medications for CNP, little efficacy has been shown in clinical
pain trials (Vranken, 2009; Urtikova et al., 2012). While initial
behavioral experiments suggested an anti-nociceptive role
for serotonin, the link between the neurotransmitter and
pain is now viewed as more complex and serotonin may
have both pro- and anti-nociceptive properties, depending
on the location and mechanism of release (central from
raphe vs. peripheral from mast cells) and the serotonergic
receptors involved (Urtikova et al., 2012; Bobinski et al.,
2015).
The NRM is the largest CNS source of spinal cord serotonin
and the PAG is its major input (Van Bockstaele et al.,
1991). Serotonergic neurons in the raphe are responsive to
inflammatory molecules and markers of CNS injury (Vanegas
and Schaible, 2004; Bobinski et al., 2015). It was shown that
stimulation of the NRM acutely increases levels of spinal cord
PKA, cAMP and CREB, signaling molecules with important roles
in development, repair and long-term potentiation. Interestingly,
these beneficial effects were elicited at quite low stimulation
frequencies (4–8 Hz), not the high frequencies (typically
50–150 Hz) used for nearly all other indications of DBS
(Hentall et al., 2006; Carballosa-Gonzalez et al., 2014). This
is relevant because while high-frequency DBS is thought to
functionally inhibit its target, low-frequency stimulation is
considered stimulatory and, in the present case, should lead
to activation of PAG and NRM and the release of modulatory
neurotransmitters in the spinal cord (Hentall and Gonzalez,
2012).
Norepinephrine (NE) has also been implicated in the
modulation of pain (Hickey et al., 2014; Li et al., 2016). NE
reuptake inhibitors or combinations of NE and 5-HT reuptake
inhibitors are common therapies for CNP and are recommended
first-line treatments for patients with SCI (Guy et al., 2016). Also,
the α2 receptor agonist clonidine is used to treat the withdrawal
effects of opioids (Siddall et al., 2000). Recent optogenetic studies
have shown that focal activation of the LC, whose major inputs
are from the PFC, amygdala, PAG and dorsal noradrenergic
bundle, may be either pro- or anti-nociceptive, suggestive of
different neuron subgroups within the LC (Hickey et al., 2014).
Consistent with this, recently Li et al. (2016), used a canine
adenoviral vector expressing channelrhodopsin2 to target ponto-
spinal NE neurons, and found a subset of ventral LC neurons
with spinal projections that is likely involved in the regulation
of nociception. Interestingly, this subgroup of LC neurons had
lower average firing rate than other noradrenergic neurons of
the LC.
DBS of the PAG could also relieve pain via neurons
that secrete β-endorphin (Siddall et al., 2000; Schofferman
et al., 2014). β-endorphin is derived from the prohormone
pro-opiomelanocortin (POMC). Cerritelli et al. (2016)
recently identified a subset of 100–200 POMC neurons in
the nucleus tractus solitarius (NTS) that, when optogenetically
stimulated, led to significant analgesic effects, that were
blocked by administration of naloxone, an opioid receptor
antagonist. Thus several highly interconnected pathways may
be involved in modulating ascending pain information and are
accessible by DBS in the PAG. For a schematic overview see
Figure 4.
Prospects for Improved Rates of Success
DBS of brainstem targets can be considered for ameliorating
severe CNP that is refractory to pharmacological treatment.
The best evidence for any pharmacological treatment of CNP
after SCI is for the anticonvulsant pregabalin (Guy et al., 2016).
However, the treatment responses to pregabalin for CNP are
not consistent. Indeed, a large recent randomized trial showed
the numbers needed to treat for >30% pain reduction was
about 7 (Cardenas et al., 2013). Long-term opioid therapy has
already proven to be a poor long-term option (Schofferman
et al., 2014). When available, non-invasive brain stimulation
methods, such as repetitive transcranial magnetic stimulation,
are preferrable over DBS. However, their efficacy is yet to be
proven in heterogeneous pain conditions and they are currently
not recommended treatment approaches for patients with CNP
related to SCI (Gao et al., 2016; Guy et al., 2016).
If DBS is to become an accepted therapy for CNP, its
efficacy and consistency need to be improved. Anecdotally
patients may experience outstanding results, but many are left
to a greater or lesser extent with the original debilitating pain
(Coffey, 2001; Boccard et al., 2013; Pereira and Aziz, 2014). It is
thus important to identify predictors of long-term efficacy and
understand mechanisms of tolerance. Comprehensive evaluation
of neuropathic pain symptoms including severity, location and
temporal pattern, and quantitative pain assessments, such as
used in this study, may help in this task, along with novel brain
imaging techniques. Thus, better defined pain phenotypes based
on comprehensive pain assessment protocols may lead to more
reliable selection of patients amenable to this therapy. Better
knowledge of responsive pain phenotypes in this notoriously
difficult patient population is also important for comparing
treatments, especially because novel therapies continue to
emerge, such as minimally invasive ablative techniques (Tiwari
et al., 2014).
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